FDA Advocacy

Learn about our work to bring the voice of people concerned about women’s health to decision-makers who create and implement health policies.

Featured Posts

Sorry, we couldn't find any content.

Browse our FDA ADVOCACY work:

  • Filter by Category:

  • Sort by:

Results for:

The public pays for more than half of the FDA's budget each year, which entitles us to have a say in the agency’s operations. Late last year, we gave your predecessor, Scott Gottlieb, a report card on his first year...

Earlier in March, the FDA sent warning letters to two breast implant manufacturers, Mentor and Sientra, citing their failure to conduct safety studies after approval. In Australia and France, authorities have been pulling textured implants off the market due to...

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240

In 2016, the FDA reclassified transvaginal mesh used to repair pelvic organ prolapse (POP) as a Class III device—the highest risk category—in response to over 20,000 adverse event reports during a three-year period alone.

Taking on Gender Bias in Clinical Trials

By: Caitlin Hoff ,, Deep Dive Articles

We have made progress as a country, but there is still work to be done. Clinical trials need to broaden their subject base and do a better job of representing all affected parties for the sake of equality and the...

Testimony Delivered at the Meeting of the FDA Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or (202) 682-6240